Overview
Medical Oncologist with a focus on breast cancer
Associate Director of Breast Cancer Clinical Research
Co-Director Duke Cardio-Oncology Program
Associate Director of Breast Cancer Clinical Research
Co-Director Duke Cardio-Oncology Program
Current Appointments & Affiliations
Adjunct Professor in the Department of Medicine
·
2024 - Present
Medicine, Medical Oncology,
Medicine
Recent Publications
CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
Journal Article Cardio Oncology · December 1, 2025 Background: Cardiovascular (CV) comorbidities and concurrent medications with risk of heart rate-corrected QT interval (QTc) prolongation can impact treatment decisions and safety discussions for patients with breast cancer. However, limited data are avail ... Full text CiteThe cardio-oncology multidisciplinary team: beyond the basics
Journal Article Cardio Oncology · December 1, 2025 A cardio-oncology multidisciplinary team is essential for the successful delivery of patient-centred care. The roles of oncologists, haematologists, and cardiologists have been clearly articulated in literature pertaining to the creation of cardio-oncology ... Full text CiteEvaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.
Journal Article Breast Cancer Res Treat · December 2025 PURPOSE: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), inc ... Full text Link to item CiteRecent Grants
ASCENT-05 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2025 - 2029A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) TBCRC-055 20-649
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2024 - 2028A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2022 - 2027View All Grants
Education, Training & Certifications
McMaster University (Canada) ·
1990
M.D.